Welcome to our dedicated page for Bio Rad Labs SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Bio-Rad is a Delaware corporation based in Hercules, California, and its filings offer detailed information on its life science research and clinical diagnostics businesses, financial performance, and material corporate events.
Investors can review current reports on Form 8-K, where Bio-Rad reports items such as quarterly financial results, supplemental earnings presentations, leadership changes, acquisitions, and other significant events. Recent 8-K filings reference the announcement of results for quarters ended June 30 and September 30, the completion of the acquisition of Stilla Technologies, and the appointment of senior executives.
In addition to current reports, users may consult annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed) for more extensive discussion of segment performance in the Life Science and Clinical Diagnostics groups, risk factors, accounting policies, and details on items such as the company’s investment in Sartorius. These filings also describe Bio-Rad’s use of non-GAAP financial measures and provide reconciliations to GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify items such as revenue trends, margin drivers, and notable changes in investments or capital structure. The platform also surfaces insider transaction reports on Form 4 when they are filed, allowing users to track equity transactions by Bio-Rad officers and directors. Together, these tools make it easier to interpret BIO’s SEC filings without reading every line of the underlying documents.
Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported transactions on Form 4 reflecting the vesting of restricted stock units and a small sale of common stock. On 09/05/2025 she received 914 restricted stock units that vested, each convertible into one share, increasing her derivative-based holdings to 914 units. On 09/06/2025 an additional 92 shares were recorded as acquired on vesting and 33 shares were sold at a price of $295.43 each. After the reported transactions her direct beneficial ownership in Class A common stock is shown as 1,489 shares on 09/06/2025 and 1,456 shares following the sale. The filing documents the standard four-year vesting schedule for the RSUs at 25% per year.
Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, acquired 6,850 restricted stock units (RSUs) on 09/05/2025, each representing a contingent right to one share of Bio-Rad Class A common stock. The RSUs were granted with a $0 per-unit price and vest over four years at 25% per year on each annual anniversary of the grant. Following the transaction, DiVincenzo beneficially owns 6,850 shares subject to these RSUs, held directly. The Form 4 was signed on 09/08/2025. No other derivatives or dispositions are reported in this filing.
Eva Anette Engelhardt, EVP and President, CDG at Bio-Rad Laboratories (BIO), reported changes in her holdings in two filings dated 09/05/2025–09/06/2025. On 09/05/2025 4,110 restricted stock units (RSUs) vested, each representing one share, and were reported as acquired. On 09/06/2025 an additional 1,152 RSUs were recorded as acquired (noted as a deemed execution/plan transaction), and separately 413 shares were disposed at a price of $295.43 on 09/06/2025. The filing shows resulting beneficial ownership counts after these transactions and is signed by Ms. Engelhardt on 09/09/2025. The RSUs vest over four years at 25% per year per the filing.
Bio-Rad Laboratories (BIO) Form 4: Courtney C. Enloe, EVP, General Counsel & Secretary, reported restricted stock units vesting and a small open-market sale. On 09/05/2025, 2,740 RSUs vested and were converted into shares; this increased reported holdings to 903.991 shares (which includes 6.5980 shares from the employee stock purchase plan). On 09/06/2025 an additional 768 RSUs were reported as acquired/vested. Also on 09/06/2025 the filing shows a disposition of 275 shares sold at $295.43 each, leaving 628.991 shares beneficially owned after the sale. The RSUs vest over four years at 25% per year.
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported insider transactions related to Class A and Class B common stock. The filing shows vested restricted stock units converted into 3,455 Class A shares and a separate purchase of 1,528 Class A shares at $295.43 each, leaving him with 443,434 Class A shares direct ownership. The report also discloses 361,466 Class B shares held directly, 13,006 Class B shares held indirectly by spouse, and 4,060,054 Class B shares held indirectly by Blue Raven Partners, L.P. Restricted stock units vest over four years at 25% per year.
Rajat Mehta, Executive Vice President, Global Commercial Operations at Bio-Rad Laboratories, Inc. (BIO), reported grants of restricted stock units on 09/05/2025. The Form 4 shows two awards: 1,827 RSUs and 5,480 RSUs, each representing the contingent right to one share of Bio-Rad Class A common stock. Both grants have a $0 per-unit reported conversion price and are held directly by the reporting person. The 1,827 RSUs vest in four equal annual installments beginning on the first anniversary of the grant date; the 5,480 RSUs vest over four years at 25% per year on each annual anniversary. The filing is signed 09/09/2025.
Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4 covering September 1, 2025. The filing shows vesting-driven acquisitions: 147 shares of Class A common stock were added on vesting of restricted stock units at no cash cost and 31, 42, and 74 RSUs vested (representing rights to 31, 42 and 74 shares). Following the transactions, Ms. Schwartz beneficially owned 1,452 shares of Class A common stock directly. The report also discloses a sale of 55 shares at $297.88 each, reducing direct holdings to 1,397 shares. The filing reflects routine executive equity compensation and a small open-market sale.
Bio-Rad insider transaction summary: EVP and President, LSG Barry James reported transactions on 09/01/2025 involving Bio-Rad Laboratories Class A common stock (BIO). The filing shows 602 shares were acquired and added to his direct holdings following the vesting of restricted stock units, increasing his direct beneficial ownership to 748.555 shares. The filing also reports a disposition of 217 shares sold at $297.88 per share, leaving 531.555 shares after that sale. Separately, the report lists restricted stock unit activity: 178 units vested (converted to 0 shares remaining), 174 units vested and remain as 174 shares, and 250 units vested increasing total RSU-derived shares to 502. The transactions are documented on a Form 4 signed 09/02/2025.
Colleen Corey, Executive Vice President, Global Human Resources of Bio-Rad Laboratories, reported insider transactions dated 09/01/2025. The filing shows 1,102 shares of Bio-Rad Class A common stock were acquired on vesting of restricted stock units at no cash price, and 398 shares were disposed of at $297.88 per share. Following the transactions, the reporting person beneficially owned 19,581 shares after the vesting event and 19,183 shares after the sale, as shown in the form.
The filing also reports restricted stock unit activity: vesting-related entries of 254, 347, and 501 RSUs tied to prior grants from 2021, 2022, and 2023, with the explanatory note that each RSU represents a contingent right to one share.
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported changes in his beneficial ownership on September 1, 2025. He acquired 6,353 Class A shares on vesting of restricted stock units and had 3,084 Class A shares disposed of at $297.88 per share. After these transactions he directly owned 444,591 Class A shares. The filing also reports direct ownership of 361,466 Class B shares and indirect holdings of 13,006 Class B shares (by spouse) and 4,060,054 Class B shares (by Blue Raven Partners, L.P.). Several restricted stock unit vesting events are noted, reflecting prior grants from 2021–2023 that vest in annual installments.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
